Foxp3 Tregs: Immune Function in Health and Disease

Foxp3-expressing regulatory T cells, commonly called Tregs, are a specialized subset of immune cells whose primary job is to prevent the rest of the immune system from attacking the body’s own tissues. The protein Foxp3 acts as a master switch that drives these cells to develop and maintain their suppressive identity, and when it malfunctions, the consequences can be fatal. But Tregs do far more than just prevent autoimmunity: they shape immune responses during infections, influence cancer outcomes, help sustain pregnancy, and change in character as we age.

How Tregs Are Born in the Thymus

Most Tregs originate in the thymus, the small organ behind the breastbone where immature T cells learn to distinguish self from non-self. What sets future Tregs apart from other T cells is how strongly they respond to the body’s own molecules. Research has shown that the degree of self-recognition is the primary factor determining whether a developing T cell becomes a Treg: cells whose receptors bind self-molecules within a certain range of strength are steered toward the regulatory lineage rather than being killed off or released as conventional T cells.¹ This range is surprisingly broad, spanning receptors that vary over tenfold in their sensitivity.

The selection process depends on strong signals through the T cell receptor, and a potassium channel called K2P18.1 appears to fine-tune that signaling. Mice with a nonfunctional version of this channel develop Tregs with a significantly narrower receptor repertoire, meaning fewer unique Tregs and potentially less comprehensive self-tolerance.² Signaling from TGF-β1, a growth factor involved in many immune processes, is also crucial for Treg development both in the thymus and in the rest of the body.³ A second population of Tregs, called peripheral or induced Tregs, can also arise outside the thymus when conventional T cells encounter certain signals in tissues like the gut. Both types rely on Foxp3 to do their work.

What Foxp3 Actually Does Inside a Treg

Foxp3 is often described as the “master transcription factor” of Tregs, which makes it sound like it single-handedly runs the show. The reality is more nuanced. Foxp3 directly binds less than ten percent of the genes associated with the Treg program.⁴ It needs a team of accessory transcription factors working alongside it, upstream and downstream, to fully establish what makes a Treg a Treg. Think of Foxp3 less as an autocratic ruler and more as a keystone in an arch: essential, but held in place by everything around it.

One of the most important discoveries about Foxp3 involves how the cell keeps its gene permanently switched on. A stretch of DNA within the Foxp3 gene, known as the Treg-specific demethylated region, undergoes a chemical modification during development that locks in Foxp3 expression for the life of the cell.⁵ This demethylation begins early in the thymus and is what guarantees long-term lineage stability, preventing the Treg from “forgetting” its identity and reverting to a conventional inflammatory T cell.⁶

How Tregs Suppress Immune Responses

Tregs have an impressive toolkit for calming down the immune system, and they rarely rely on just one mechanism at a time. Their suppressive strategies can be grouped into a few broad categories.

• Anti-inflammatory molecules: Tregs secrete cytokines like IL-10 and TGF-β that directly dampen the activity of nearby immune cells. In a mouse model of colitis, blocking either IL-10 or TGF-β completely abolished the therapeutic effect of transferred Tregs.⁷
• CTLA-4 and ligand stripping: Tregs express high levels of a surface protein called CTLA-4, which physically strips costimulatory molecules off the surface of antigen-presenting cells through a process called trans-endocytosis. The captured molecules are then destroyed inside the Treg, leaving antigen-presenting cells unable to properly activate other T cells.⁸
• IL-2 consumption: Tregs express very high levels of the IL-2 receptor, which lets them absorb IL-2 from the surrounding environment. Since other T cells need IL-2 to survive and proliferate, Tregs effectively starve their neighbors. When IL-2 availability is boosted experimentally, Tregs respond with increased suppressive capacity and higher expression of molecules like CTLA-4 and CD39.⁹
• Surface co-inhibitory molecules: Beyond CTLA-4, Tregs carry other inhibitory receptors like PD-1 and TIGIT, along with costimulatory molecules like ICOS and GITR, that help modulate interactions with different immune cell types.¹⁰

No single mechanism is solely responsible for Treg function. The mix of tools a Treg deploys depends on where it is in the body and what kind of immune response it is trying to restrain.

When Tregs Lose Their Identity

Treg stability is not absolute. Under certain inflammatory conditions, Tregs can lose Foxp3 expression and, with it, their suppressive function. This phenomenon, sometimes called Treg plasticity, has been documented across many experimental settings.¹¹ When Tregs shed their regulatory identity, they can convert into cells that actually promote inflammation, potentially worsening the very conditions they are supposed to control.

A particularly telling experiment involved Tregs expressing a form of Foxp3 missing a specific region encoded by exon 2. These cells performed perfectly well in standard laboratory suppression tests, yet when transferred into mice lacking their own T cells, they proved unstable and caused autoimmunity.³ The finding illustrates a critical point: a Treg can appear functional in a dish yet fail catastrophically in a living body. Stability and function are not the same thing, and understanding how to maintain Treg stability in hostile environments is one of the field’s central challenges.

IPEX Syndrome and the Cost of Losing Foxp3

The clearest evidence of how essential Foxp3-expressing Tregs are comes from a rare genetic condition called IPEX syndrome, which stands for immunodysregulation, polyendocrinopathy, enteropathy, X-linked. Children born with mutations in the FOXP3 gene fail to develop functional Tregs, and the consequences are devastating: severe autoimmune attacks on the gut, skin, thyroid, and pancreas, frequently resulting in death within the first two years of life without treatment.¹²

Because FOXP3 sits on the X chromosome, IPEX overwhelmingly affects boys. The disease spectrum has broadened as genetic testing has improved: not all FOXP3 mutations cause the same severity, and some patients present with milder or atypical symptoms. Hematopoietic stem cell transplantation remains the main curative option, though gene therapy strategies that would correct the FOXP3 mutation directly are in development.¹³ IPEX has also served as a crucial natural experiment for immunologists: studying patients with different FOXP3 mutations has helped map which parts of the protein are essential for different Treg functions.¹⁴

The Treg Problem in Cancer

Tregs play a double-edged role in cancer. In healthy tissue, their ability to suppress immune responses prevents autoimmunity. In a tumor, that same suppressive activity helps the cancer hide from immune attack. Tregs accumulate in the tumor microenvironment and contribute to immune evasion and cancer progression.¹⁵ High Treg infiltration in tumors is associated with worse outcomes across many cancer types.

The challenge for cancer immunotherapy is that you cannot simply wipe out all Tregs systemically without triggering dangerous autoimmune side effects. Current research focuses on selectively depleting or reprogramming only the Tregs within the tumor. One promising approach targets CCR8, a surface receptor that is preferentially expressed on tumor-infiltrating Tregs but not on Tregs elsewhere in the body. Anti-CCR8 therapies have shown the ability to reduce intratumoral Tregs without triggering autoimmunity.¹⁶ Another strategy involves reprogramming Tregs inside the tumor to switch from suppressive to inflammatory behavior, effectively turning the cancer’s shield into a weapon against it.¹⁷

Tregs in Pregnancy

A developing fetus carries genes from both parents, which means it displays molecules that the mother’s immune system should recognize as foreign. The fact that most pregnancies proceed without the mother’s immune system attacking the fetus is partly thanks to Tregs that accumulate at the interface between maternal and fetal tissue. A recently identified subset, CCR8-positive decidual Tregs, appears to be particularly important for maintaining this tolerance. These cells are enriched in the uterine lining during early pregnancy, and women experiencing recurrent pregnancy loss have significantly fewer of them.¹⁸

In mouse experiments, depleting CCR8-positive Tregs from the uterus increased fetal loss, while transferring them into abortion-prone mice rescued pregnancies. The signal that recruits these Tregs, a chemokine called CCL1, is produced mainly by a specific type of natural killer cell in the uterus and is reduced in women with recurrent pregnancy loss. Fetal cells themselves also appear to actively promote Treg expansion: when extravillous trophoblasts (the fetal cells that invade the uterine wall) are co-cultured with maternal T cells, the proportion of Foxp3-positive Tregs increases.¹⁹ The fetus, in other words, is not a passive bystander: it actively shapes the mother’s immune environment to protect itself.

Tregs During Infections

During an infection, the immune system faces a tradeoff. A strong inflammatory response clears pathogens efficiently but can destroy healthy tissue in the process. Tregs mediate this tradeoff, and the results are not always straightforward. In some viral infections, Tregs limit the effectiveness of the immune response against the pathogen, potentially allowing the virus to persist longer. In other, arguably more common scenarios, Tregs prevent the immune response from spiraling into tissue-damaging inflammation that does more harm than the pathogen itself.²⁰

A recent study examining localized herpes simplex virus infection in mice found that Tregs restrict bystander inflammation not just at the site of infection but also in distant tissues. When Tregs were depleted, mice developed increased T cell infiltration and tissue damage in both the vagina (the infection site) and the central nervous system. Interestingly, the same study showed that Tregs were actually necessary for generating a robust virus-specific response at the mucosal site of infection, suggesting they help focus the immune response rather than simply blunting it.²¹

Tregs Beyond the Immune System

Tregs do not just circulate in the blood waiting for immune emergencies. Distinct populations take up permanent residence in specific tissues, where they perform functions that go well beyond classical immune suppression. Adipose tissue Tregs are a well-studied example. These cells have a unique gene expression profile compared to their circulating counterparts and have been linked to metabolic regulation, earning attention from researchers outside traditional immunology.²² Their decline in obesity has been associated with the chronic low-grade inflammation that drives insulin resistance, though the exact causal chain is still being worked out.

The gut is another major site of tissue-resident Treg activity, and here the microbiome plays a direct role. Short-chain fatty acids produced by gut bacteria, particularly butyrate, promote Treg generation and suppress inflammatory T cell subsets. Butyrate does this by activating specific receptors on immune cells, tipping the balance toward tolerance rather than inflammation.²³ This connection between diet, gut bacteria, and immune regulation helps explain why disruptions to the microbiome are increasingly linked to autoimmune conditions like rheumatoid arthritis and inflammatory bowel disease.

Tregs and Aging

The Treg compartment does not stay static over a lifetime. As people age, the frequency of naturally occurring Tregs in the blood tends to increase, while the generation of new induced Tregs appears to decline.²⁴ This shift may sound paradoxical: if Tregs suppress immunity, having more of them should make the immune system weaker, not more inflammatory. Yet older adults are known for both increased susceptibility to infections and cancer (suggesting weakened immunity) and a chronic, low-grade inflammatory state sometimes called “inflammaging.”

The emerging picture is that the accumulating Tregs in older adults may be part of the problem. Their increased numbers could suppress the immune system’s ability to fight infections and detect tumors, while their functional quality may simultaneously deteriorate, failing to control the chronic background inflammation that characterizes aging.²⁵ Whether age-related Treg changes are a cause or a consequence of immune decline remains an open question, but disentangling this relationship is important for understanding why older adults respond differently to vaccines, infections, and immunotherapies.

Transplantation and Adoptive Treg Therapy

One of the earliest clinical hopes for Tregs was in organ transplantation. Experimental models have shown that Tregs can control both acute and delayed graft rejection, raising the possibility that boosting Treg activity after a transplant could reduce or even eliminate the need for lifelong immunosuppressive drugs.²⁶ Early clinical trials using infusions of the patient’s own expanded Tregs have shown acceptable safety profiles, but moving from safety to genuine clinical benefit has been slow.

The field is now shifting toward engineering Tregs for greater precision. Rather than infusing large numbers of generic Tregs (a polyclonal approach), researchers are building Tregs equipped with engineered receptors that direct them specifically to the transplanted organ or to the tissue under autoimmune attack. Chimeric antigen receptor Tregs, analogous to the CAR-T cells used in cancer treatment but designed to suppress rather than kill, have shown encouraging results in animal models of autoimmunity.²⁷ These antigen-specific approaches are expected to be both safer and more effective than polyclonal strategies, because they concentrate suppressive activity where it is needed rather than dampening the immune system broadly.

The Challenge of Identifying Tregs

A persistent practical headache in Treg research and therapy is that Foxp3 is a nuclear protein, meaning you have to break cells open to detect it. You cannot sort live Tregs based on Foxp3 expression alone. Researchers rely instead on combinations of surface markers like CD25, CD127, CTLA-4, and others. But none of these markers is truly Treg-specific: activated conventional T cells can temporarily express many of the same molecules. Even newer candidates like GITR, 4-1BB, TIGIT, and CD39, which help distinguish Tregs from activated conventional T cells, are still expressed on a small fraction of non-Tregs.¹⁰

This ambiguity matters for clinical applications. When you expand Tregs in the lab for infusion into a patient, contamination with conventional T cells that happen to look like Tregs could undermine the therapy or even cause harm. And when researchers report Treg frequencies in disease studies, the particular marker panel they use can shift the numbers substantially. Chemokine receptors like CCR8 and CCR4 have gained attention precisely because they appear more enriched on tissue-specific Treg populations, such as the decidual Tregs involved in pregnancy or the tumor-infiltrating Tregs targeted by cancer immunotherapies. As single-cell technologies improve, the field is moving toward defining Tregs not by one or two markers but by full transcriptional profiles, which should make both research and clinical applications more precise.